Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts, N Engl J Med, vol.300, pp.1068-1073, 1979. ,
Graft-versus-host disease, Lancet, vol.373, pp.1550-1561, 2009. ,
Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation, Blood, vol.75, pp.1011-1016, 1990. ,
Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation, Blood, vol.89, pp.3048-3054, 1997. ,
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy, Blood, vol.89, pp.4531-4536, 1997. ,
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases, Blood, vol.91, pp.756-763, 1998. ,
Reduced-intensity conditioning with fludarabin, oral busulfan, and thymoglobulin allows longterm disease control and low transplant-related mortality in patients with hematological malignancies, Exp Hematol, vol.38, pp.1241-1250, 2010. ,
Selection designs for pilot studies based on survival, Biometrics, vol.49, pp.391-398, 1993. ,
Handbook of Statistics in Clinical Oncology, pp.119-127, 2001. ,
Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation, Haematologica, vol.92, pp.1004-1006, 2007. ,
Clinical manifestations of graft-versus-host disease in human recipients from HL-A-matched sibling donors, Transplantation, vol.18, pp.295-304, 1974. ,
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, vol.85, pp.365-376, 1993. ,
Nonparametric estimation from incomplete observations, J Am Stat Assoc, vol.53, pp.457-481, 1957. ,
Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis, Cancer, vol.115, pp.4715-4726, 2009. ,
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning, Blood, vol.110, pp.2744-2748, 2007. ,
Estimation of integrated transition hazards and stage occupation probabilities for non-Markov systems under dependent censoring, Biometrics, vol.58, pp.792-802, 2002. ,
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation, Blood, vol.104, pp.865-872, 2004. ,
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, J Clin Oncol, vol.28, pp.2859-2867, 2010. ,
Tandem autologous/ reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up, J Clin Oncol, vol.29, pp.3016-3022, 2011. ,
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life, Biol Blood Marrow Transplant, vol.17, pp.1490-1496, 2011. ,
Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation, Blood, vol.94, pp.1131-1136, 1999. ,
Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects, Bone Marrow Transplant, vol.35, pp.225-231, 2005. ,
Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond, Leukemia, vol.21, pp.1387-1394, 2007. ,
Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity ,